Brigatinib (Brigatinib) manufacturer reveals secrets

Brigatinib (Brigatinib), a second-generation tyrosine kinase inhibitor (TKI) targeting ALK-positive non-small cell lung cancer (NSCLC), the manufacturer behind it is also attracting attention. This drug was originally developed by the American biopharmaceutical company Arbor Pharmaceuticals, and was later acquired by the Japanese pharmaceutical giant - Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical Company Limited) and continued its development and marketing.

Takeda Pharmaceuticals, a pharmaceutical company headquartered in Osaka, Japan, has a history of more than two centuries since its founding in1781. It is known for its innovation and superior product development capabilities in the pharmaceutical and biopharmaceutical fields and is one of the world's leading pharmaceutical companies. Takeda Pharmaceuticals operates around the world and is committed to providing innovative drug treatment options to patients in the treatment areas of oncology, gastroenterology, neuroscience and rare diseases.

Brigatinib during early stages of development byArbor Pharmaceuticals, it has demonstrated significant efficacy in clinical trials in patients with ALKpositiveNSCLC. In 2017, Takeda Pharmaceuticals completed the acquisition of Arbor Pharmaceuticals, thus obtaining the global development and commercialization rights of Brigatinib (Brigatinib) . Since then, Takeda Pharmaceuticals has continued to invest a lot of resources in clinical trials to further verify the efficacy and safety of brigatinib (brigatinib) and promote its launch and application in the global market.

Today, brigatinib (Brigatinib) has been approved for marketing in many countries and regions around the world, including the United States, the European Union, Japan and China. It has become an important drug option for the treatment of ALKpositive NSCLC patients, especially for those who are resistant to first-generation ALK inhibitors such as crizotinib (For patients who are resistant to Crizotinib (Brigatinib), Brigatinib (Brigatinib) has brought new hope. Its excellent efficacy and good tolerability have opened a new treatment chapter for many lung cancer patients.